Search results for " OUTCOMES"

showing 10 items of 356 documents

Breastfeeding Practices Influence the Breast Milk Microbiota Depending on Pre-Gestational Maternal BMI and Weight Gain over Pregnancy

2021

Breastfeeding is critical for adequate neonatal microbial and immune system development affecting neonate health outcomes in the short and long term. There is a great interest in ascertaining which are the maternal factors contributing to the milk microbiota and the potential relevance for the developing infant. Thus, our study aimed to characterize the effect of mixed and exclusive breastfeeding practices on the milk microbiota and to determine the impact of pre-pregnancy body mass index (BMI) and weight gain over pregnancy on its composition. Breast milk samples from 136 healthy women were collected within the first month post-partum and milk microbiota profiling was analyzed by 16S rRNA …

0301 basic medicineAdultbreastfeeding030106 microbiologyBreastfeedingBreastfeedingbody mass indexBreast milkHealth outcomesArticle03 medical and health sciencesfluids and secretionsEnvironmental healthmedicineHumansTX341-641Body mass indexBifidobacterium2. Zero hungerPregnancyNutrition and DieteticsbiologyBacteriaMilk Humanbusiness.industryNutrition. Foods and food supplyMicrobiotabiology.organism_classificationmedicine.diseaseGestational Weight Gain3. Good health030104 developmental biologyBreast FeedingGestationFemalemedicine.symptombusinessBody mass indexWeight gainFood ScienceNutrients
researchProduct

Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directo…

2020

Cardiovascular diseases, in particular hypertension, as well as the cardiovascular treatment with Renin-Angiotensin System inhibitors such as Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin Receptor Blockers (ARBs), are claimed once again as mechanisms of Severe Acute Respiratory Syndrome (SARS) during the COVID-19 outbreak due to Cov-2 epidemics. In vitro studies are available to support the eventual role of ACE inhibitors and ARBs in both the promotion and antagonism of the disease. The available literature, indeed, presents contrasting results, all concentrated in experimental models. Evidence in humans is lacking that those mechanisms are actually occurring in the present…

0301 basic medicineAngiotensin-Converting Enzyme InhibitorsDiseaseoutcomescardiovascular diseases; COVID-19; hypertension; infection; outcomes; Betacoronavirus; COVID-19; Cardiovascular Diseases; Humans; Hypertension; Italy; SARS-CoV-2; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Coronavirus Infections; Pandemics; Pneumonia Viral; Renin-Angiotensin SystemRenin-Angiotensin System0302 clinical medicinecardiovascular diseaseViralAngiotensin Receptor AntagonistsbiologyAngiotensin Receptor AntagonistAntihypertensive AgentItalyoutcomeAngiotensin Receptor BlockersCoronavirus InfectionsCardiology and Cardiovascular MedicineHumanmedicine.medical_specialtyhypertensionCoronavirus disease 2019 (COVID-19)Pneumonia ViralBetacoronavirusAngiotensin Receptor Antagonists03 medical and health sciencesPharmacotherapyRenin–angiotensin systemInternal MedicinemedicineHumansIntensive care medicinePandemicsAntihypertensive Agentsoutcomes.BetacoronaviruPandemicCoronavirus InfectionSARS-CoV-2business.industryOutbreakCOVID-19Angiotensin-Converting Enzyme InhibitorAngiotensin-converting enzymePneumoniacardiovascular diseases; COVID-19; hypertension; infection; outcomesinfectioncardiovascular diseases030104 developmental biologybiology.proteincardiovascular diseases; COVID-19; hypertension; infection; outcomes; betacoronavirus; cardiovascular diseases; humans; hypertension; Italy; angiotensin receptor antagonists; angiotensin-converting enzyme inhibitors; antihypertensive agents; coronavirus infections; pandemics; pneumonia viral; renin-angiotensin systembusiness030217 neurology & neurosurgery
researchProduct

Apolipoprotein B is regulated by gonadotropins and constitutes a predictive biomarker of IVF outcomes

2016

Background Follicular fluid (FF) is an important micro-environment influencing oocyte growth, its development competence, and embryo viability. The FF content analysis allows to identify new relevant biomarkers, which could be predictive of in vitro fertilization (IVF) outcomes. Inside ovarian follicle, the amount of FF components from granulosa cells (GC) secretion, could be regulated by gonadotropins, which play a major role in follicle development. Methods This prospective study included 61 female undergoing IVF or Intra-cytoplasmic sperm injection (ICSI) procedure. Apolipoprotein B (APOB) concentrations in follicular fluid and APOB gene and protein expression in granulosa cells from rep…

0301 basic medicineApolipoprotein Bmedicine.medical_treatment[SDV]Life Sciences [q-bio]Human follicular fluidOocyte RetrievalChorionic GonadotropinHuman chorionic gonadotropinFollicle-stimulating hormone0302 clinical medicineEndocrinologyProspective Studies030219 obstetrics & reproductive medicinebiologyObstetrics and Gynecology[SDV] Life Sciences [q-bio]Treatment Outcomemedicine.anatomical_structureFemalelipids (amino acids peptides and proteins)Apolipoprotein BEmbryo qualityAdultmedicine.medical_specialtyendocrine systemEmbryonic DevelopmentFertilization in Vitro03 medical and health sciencesOvulation InductionInternal medicinemedicineIVF outcomesHumansOvarian follicleApolipoproteins BHuman granulosa cellsGranulosa CellsIn vitro fertilisation[ SDV ] Life Sciences [q-bio]ResearchEmbryo MammalianOocyteFollicular fluidFollicular Fluid030104 developmental biologyEndocrinologyReproductive MedicineFertilizationbiology.proteinFollicle Stimulating HormoneBiomarkersGonadotropinsDevelopmental BiologyReproductive Biology and Endocrinology
researchProduct

DEBATE: Do interventions based on behavioral theory work in the real world?

2019

Abstract Background Behavioral scientists suggest that for behavior change interventions to work effectively, and deliver population-level health outcomes, they must be underpinned by behavioral theory. However, despite implementation of such interventions, population levels of both health outcomes and linked behaviors have remained relatively static. We debate the extent to which interventions based on behavioral theory work in the real world to address population health outcomes. Discussion Hagger argues there is substantive evidence supporting the efficacy and effectiveness of interventions based on behavioral theory in promoting population-level health behavior change in the ‘real world…

0301 basic medicineComparative Effectiveness ResearchEfficacyDebateApplied psychologyPopulationHealth BehaviorPsychological interventionMedicine (miscellaneous)Behavioural sciencesPhysical Therapy Sports Therapy and RehabilitationEffectivenessPopulation healthHealth behaviour changeMedical and Health SciencesEducation03 medical and health sciences0302 clinical medicineBehavior TherapyBehavioral and Social ScienceHumans030212 general & internal medicineCausationeducationlcsh:RC620-627education.field_of_studyBehavior030109 nutrition & dieteticsNutrition and DieteticsPopulation HealthBehavioural interventionsPreventionlcsh:Public aspects of medicineBehavior changelcsh:RA1-1270Health outcomeslcsh:Nutritional diseases. Deficiency diseasesParadigm shiftImplementationSpiteGeneric health relevancePublic HealthPsychologyInternational Journal of Behavioral Nutrition and Physical Activity
researchProduct

Uterine microbiome—low biomass and high expectations†

2018

AbstractThe existence of different bacterial communities throughout the female reproductive tract has challenged the traditional view of human fetal development as a sterile event. There is still no consensus on what physiological microbiota exists in the upper reproductive tract of the vast majority of women who are not in periods of infection or pregnancy, and the role of bacteria that colonize the upper reproductive tract in uterine diseases or pregnancy outcomes is not well established. Despite published studies and advances in uterine microbiome sequencing, some study aspects—such as study design, sampling method, DNA extraction, sequencing methods, downstream analysis, and assignment …

0301 basic medicineGenital Neoplasms Femalemedicine.medical_treatmentReproductive tractUterusPhysiologyBiology03 medical and health sciences0302 clinical medicinePregnancymedicineHumansBiomassPrecision MedicineUterine microbiomePregnancy outcomesPregnancy030219 obstetrics & reproductive medicineAssisted reproductive technologyMicrobiotaUterusFemale infertilityGenitalia FemaleCell BiologyGeneral Medicinemedicine.diseasePregnancy Complications030104 developmental biologymedicine.anatomical_structureReproductive MedicineHuman fetalFemaleGenital Diseases FemaleBiology of Reproduction
researchProduct

A multidimensional approach to frailty in older people

2020

Frailty is an important factor determining a higher risk of adverse health outcomes in older adults. Although scientific community in the last two decades put a lot of effort for its definition, to date no consensus was reached on its assessment. The mainstream thinking describes frailty as a loss of physical functions or as accumulation of multiple deficits. Recently, a novel conceptual model of frailty has emerged based on the loss of harmonic interaction between multiple domains (also referred as dimensions) including genetic, biological, functional, cognitive, psychological and socio-economic domain that ultimately lead to homeostatic instability. Therefore, the multidimensional aspects…

0301 basic medicineGerontologyAgingInstitutionalisationFrail Elderlymedia_common.quotation_subjectFrail Older AdultsPopulationComprehensive geriatric assessmentHealth outcomesBiochemistryArticle03 medical and health sciences0302 clinical medicineMultidimensional prognostic indexHumanseducationGeriatric AssessmentMolecular BiologyAgedmedia_commonAged 80 and overeducation.field_of_studyFrailtyGeriatric assessmentCognitionPrognosis030104 developmental biologyNeurologyConceptual modelPsychologyOlder people030217 neurology & neurosurgeryBiotechnologyAgeing Research Reviews
researchProduct

Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus.

2021

International audience; Background: Recent years have witnessed a considerable increase in clinical trials of new investigational agents for Fabry disease (FD). Several trials investigating different agents are currently in progress; however, lack of standardisation results in challenges to interpretation and comparison. To facilitate the standardisation of investigational programs, we have developed a common framework for future clinical trials in FD.Methods and findings: A broad consensus regarding clinical outcomes and ways to measure them was obtained via the Delphi methodology. 35 FD clinical experts from 4 continents, representing 3389 FD patients, participated in 3 rounds of Delphi p…

0301 basic medicineMaleDelphi TechniqueEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]Delphi methodDisease030105 genetics & heredityKidneyBiochemistry0302 clinical medicineEndocrinologyClinical outcomesClinical Trials as TopicGlobosidesTrihexosylceramidesMiddle Aged3. Good healthClinical trialIsoenzymesTreatment OutcomeInclusion and exclusion criteriaSecondary Outcome MeasureFemaleAdultmedicine.medical_specialtyConsensusLysosomal storage disorders03 medical and health sciencesQuality of life (healthcare)Inherited metabolic disordersGeneticsmedicineHumansEnzyme Replacement TherapyIntensive care medicineMolecular BiologyFabry diseaseSphingolipidsbusiness.industryClinical study designmedicine.diseaseFabry diseaseClinical trialDelphi consensusalpha-GalactosidaseQuality of LifeFabry DiseaseGlycolipidsbusiness030217 neurology & neurosurgeryMolecular genetics and metabolism
researchProduct

KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting

2020

In advanced stage non-small cell lung cancer (NSCLC) patients, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) testing may soon acquire a predictive significance to select patients for AMG510 treatment. Since tissue samples are not always available, liquid biopsy may represent a viable option for KRAS testing. Here, we review the last three years clinical practice performed on 194 plasma based liquid biopsies by next generation sequencing (NGS) SiRe(®) panel. In particular, 36 (18.6%) KRAS mutated cases were identified, with an overall median allelic frequency of 5.0% (ranging between 0.2% and 46.8%). No concomitant mutations were observed in the other NSCLC clinical relevant genes includ…

0301 basic medicinePulmonary and Respiratory MedicineAMG510Settore MED/06 - Oncologia MedicaViral Oncogenemedicine.disease_cause03 medical and health sciencesBasal (phylogenetics)0302 clinical medicineG12CMedicineEpidermal growth factor receptorLiquid biopsyLung cancerneoplasmsMutationbiologyLiquid biopsybusiness.industryKirsten Rat Sarcoma Viral Oncogene Homolog (KRAS)Review Article on Improving Outcomes in Lung Cancer Through Early Diagnosis and Smoking Cessationmedicine.diseaseBasal setting030104 developmental biologyNext generation sequencing (NGS)030220 oncology & carcinogenesisCancer researchbiology.proteinBiomarker (medicine)KRASLung cancerbusiness
researchProduct

Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors

2020

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors are so called “incretin-based therapies” (IBTs) that represent innovative therapeutic approaches and are commonly used in clinical practice for the treatment of type 2 diabetes mellitus (T2DM). The cardiovascular outcome trials (CVOTs) have provided useful information that has helped to shape changes in clinical practice guidelines for the management of T2DM. At the same time, the mechanisms that may explain the nonglycemic and cardiovascular (CV) benefits of these medications are still being explored. A summary of the main findings from CVOTs performed to-date with particular emphasis on vari…

0301 basic medicineendocrine systemmedicine.medical_specialtyDipeptidyl Peptidase 4Endocrinology Diabetes and MetabolismIncretin030209 endocrinology & metabolismClass effectBody weightCardiovascular SystemIncretinsGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineType 2 diabetes mellitusmedicineAnimalsHumansIntensive care medicineGlucagon-like peptide 1 receptorDipeptidyl-Peptidase IV Inhibitorsbusiness.industryDPP-4 Inhibitorsdigestive oral and skin physiologyType 2 Diabetes MellitusCardiovascular riskDPP4- inhibitorClinical Practice030104 developmental biologyCardiovascular DiseasesGlucagon-like peptide 1 receptor agonistbusinessCardiovascular outcomesMetabolism
researchProduct

Autosomal Recessive Hypercholesterolemia

2018

Abstract Background Autosomal recessive hypercholesterolemia (ARH) is a rare lipid disorder characterized by premature atherosclerotic cardiovascular disease (ASCVD). There are sparse data for clinical management and cardiovascular outcomes in ARH. Objectives Evaluation of changes in lipid management, achievement of low-density lipoprotein cholesterol (LDL-C) goals and cardiovascular outcomes in ARH. Methods Published ARH cases were identified by electronic search. All corresponding authors and physicians known to treat these patients were asked to provide follow-up information, using a standardized protocol. Results We collected data for 52 patients (28 females, 24 males; 31.1 ± 17.1 years…

0301 basic medicinemedicine.medical_specialtyStatinAtherosclerotic cardiovascular diseasebusiness.industrymedicine.drug_class030204 cardiovascular system & hematologyLomitapide03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicineEzetimibechemistryAutosomal Recessive HypercholesterolemiaInternal medicinemedicineEffective treatmentlipids (amino acids peptides and proteins)In patientCardiology and Cardiovascular MedicinebusinessCardiovascular outcomesmedicine.drugJournal of the American College of Cardiology
researchProduct